MetaCap

Eledon Pharmaceuticals Inc. (ELDN)

NASDAQ: ELDNHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.78-0.12 (-6.32%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ELDN stock chart

Technical analysis

Key statistics

All statistics
Market cap
$150.34M
EPS (TTM)
-$0.73
52-week range
1.39 – 4.49
Day range
1.76 – 2.00
Volume / Avg
1.29M / 931.77K
Beta
—

52-week range

$1.39$4.49

ELDN stock today

On Nov 20, ELDN ended the session at $1.78, shedding $0.12 (6.32%), versus the S&P 500's 3.70% decline. Shares are 60.4% below their 52-week high of $4.49, set on Jun 22, 2026 and 28.5% above the 52-week low of $1.39, near the bottom of the past year's range. ELDN is up 17.9% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 23.6%.

Eledon Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$0.73), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Eledon Pharmaceuticals

Company profile

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. David-Alexandre C. Gros M.D., Ph.D.
Headquarters
Irvine, CA
Employees
33
IPO year
2014
Website
eledon.com

Financial highlights

Full financials

Eledon Pharmaceuticals reported a net loss of $45.6 million, compared with a loss of $36.2 million a year earlier. Diluted earnings per share came in at -$0.52.

Eledon Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-45.62M$-36.18M$-116.54M$-87.97M$-34.51M
EPS (diluted)$-0.52$-0.66$-4.73$-6.16$-2.33

Analyst forecast

Forecast

Consensus (6 analysts)

strong_buy

Avg. price target

$9.00+405.62%

  • Strong buy 0
  • Buy 6
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $7.00High $12.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 13, 2026
EPS actual vs est.
$-0.03 vs $-0.20
Surprise
+85.00%

ELDN news

All ELDN news

Eledon Pharmaceuticals peers

Health Care sector
ELDN peer companies
CompanyPrice% ChgMarket capCompare
RNAAtrium Therapeutics Inc.6.92-0.86%$149.27Mvs ELDN
IFRXInflaRx N.V.1.04-4.59%$153.26Mvs ELDN
VRXAVeraxa Biotech AG1.04+0.97%$147.06Mvs ELDN
PRQRProQR Therapeutics N.V.1.04-0.95%$146.98Mvs ELDN
ORMPOramed Pharmaceuticals Inc.3.57-3.25%$155.24Mvs ELDN
BBOTBridgeBio Oncology Therapeutics Inc.1.81-2.69%$145.25Mvs ELDN
EMISEmmis Acquisition Corp. Class A10.36+0.15%$163.36Mvs ELDN
ALXOALX Oncology Holdings Inc.1.06+3.92%$137.03Mvs ELDN

Indexes, lists and sector

Eledon Pharmaceuticals stock FAQ

What is Eledon Pharmaceuticals's stock price today?

ELDN last traded at $1.78 as of Nov 20, 4:00 PM EST, down 6.32% on the day. Prices are delayed at least 15 minutes.

Does Eledon Pharmaceuticals pay a dividend?

No. Eledon Pharmaceuticals does not currently pay a regular cash dividend.

Who is Eledon Pharmaceuticals's CEO?

Dr. David-Alexandre C. Gros M.D., Ph.D. is the chief executive officer of Eledon Pharmaceuticals Inc., which has about 33 employees.

Has ELDN ever split its stock?

Yes. The most recent ELDN stock split was a 1-for-18 split on Oct 5, 2020, one of 2 splits on record.

What is the ELDN 52-week high?

The 52-week high for ELDN is $4.49 and the 52-week low is $1.39. The stock is currently 60.4% below its high.

Compare ELDN